دورية أكاديمية
أعرض في EDS

Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189

التفاصيل البيبلوغرافية
العنوان: Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189
المؤلفون: Gadgeel, Shirish, Grey, Jhanelle, Rizzo, Maria Teresa, Peterson, Patrick, Kim, Jongseok, Rodríguez-Abreu, Delvys
المصدر: Hematology/Oncology Meeting Abstracts
بيانات النشر: Henry Ford Health Scholarly Commons
سنة النشر: 2021
المجموعة: Henry Ford Health System Scholarly Commons
مصطلحات موضوعية: endogenous compound, pembrolizumab, pemetrexed, placebo, programmed death 1 ligand 1, adult, cancer patient, cancer size, clinical trial, conference abstract, controlled study, distant metastasis, drug efficacy, drug therapy, female, gene expression, health care quality, human, major clinical study, male, non small cell lung cancer, organ systems, protein expression, randomized controlled trial, vascular guide wire, Hematology
الوصف: Background: Pemetrexed (pem) and platinum (plat) plus pembrolizumab (pembro) showed clinical improvement in metastatic nonsquamous (NSQ) non-small-cell lung cancer (NSCLC). The aim of this analysis was to assess the clinical benefit of pem+plat+pembro in patients by tumor burden at baseline. Methods: The intention-to-treat population was analysed. Patients were randomized pem+plat+pembro (n=410) or pem+plat+placebo (n=206). The data cut-off date was May 20, 2019. OS, PFS, PFS-2, and ORR were evaluated by Kaplan-Meier and univariate Cox methods within subgroups identified by extent of distant metastasis (M1a vs. M1b), median number (≤3 vs. >3) of organ systems with lesions, and severity score of patient-reported symptoms (below median vs. above median) at baseline. These subgroup analyses were also replicated within PD-L1 TPS subgroups (<1%, 1-49%, ≥50%). Results: A consistent benefit in OS, PFS, PFS-2 and ORR was observed in the pem+plat+pembro treatment arm, compared to the pem+plat+placebo arm, irrespective of staging (M1a vs. M1b), number (≤ 3 vs. 3) of organ systems with lesions and severity of patient-reported symptoms (Table 1). Results by PD-L1 expression in the subgroups were generally consistent regardless of the level of expression. Conclusions: Pem+plat+pembro demonstrated consistent clinical benefit across all subgroups analysed regardless of baseline tumor burden. These results continue to support pem+plat+pembro as a standard of care in metastatic NSQ-NSCLC.
نوع الوثيقة: text
اللغة: unknown
العلاقة: https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/138Test; http://sfxhosted.exlibrisgroup.com/hfhs?sid=EMBASE&issn=15387445&id=doi:10.1158%2F1538-7445.AM2021-442&atitle=Pemetrexed+and+platinum+plus+pembrolizumab+in+patients+with+metastatic+non-squamous+non-small+cell+lung+cancer+by+tumor+burden+at+baseline%3A+A+post-hoc+efficacy+analysis+of+KEYNOTE-189&stitle=Cancer+Res.&title=Cancer+Research&volume=81&issue=13+SUPPL&spage=&epage=&aulast=Gadgeel&aufirst=Shirish&auinit=S.&aufull=Gadgeel+S.&coden=&isbn=&pages=-&date=2021&auinit1=S&auinitmTest=
الإتاحة: https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/138Test
رقم الانضمام: edsbas.D74B2BF8
قاعدة البيانات: BASE
ResultId 1
Header edsbas
BASE
edsbas.D74B2BF8
857
3
Academic Journal
academicJournal
856.820373535156
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.D74B2BF8&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/138# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189 )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gadgeel%2C+Shirish%22&quot;&gt;Gadgeel, Shirish&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Grey%2C+Jhanelle%22&quot;&gt;Grey, Jhanelle&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Rizzo%2C+Maria+Teresa%22&quot;&gt;Rizzo, Maria Teresa&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Peterson%2C+Patrick%22&quot;&gt;Peterson, Patrick&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kim%2C+Jongseok%22&quot;&gt;Kim, Jongseok&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Rodr&#195;&#173;guez-Abreu%2C+Delvys%22&quot;&gt;Rodr&#195;&#173;guez-Abreu, Delvys&lt;/searchLink&gt; )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Hematology/Oncology Meeting Abstracts )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Henry Ford Health Scholarly Commons )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Henry Ford Health System Scholarly Commons )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22endogenous+compound%22&quot;&gt;endogenous compound&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22pembrolizumab%22&quot;&gt;pembrolizumab&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22pemetrexed%22&quot;&gt;pemetrexed&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22placebo%22&quot;&gt;placebo&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22programmed+death+1+ligand+1%22&quot;&gt;programmed death 1 ligand 1&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22adult%22&quot;&gt;adult&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22cancer+patient%22&quot;&gt;cancer patient&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22cancer+size%22&quot;&gt;cancer size&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22clinical+trial%22&quot;&gt;clinical trial&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22conference+abstract%22&quot;&gt;conference abstract&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22controlled+study%22&quot;&gt;controlled study&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22distant+metastasis%22&quot;&gt;distant metastasis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22drug+efficacy%22&quot;&gt;drug efficacy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22drug+therapy%22&quot;&gt;drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22female%22&quot;&gt;female&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22gene+expression%22&quot;&gt;gene expression&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22health+care+quality%22&quot;&gt;health care quality&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22human%22&quot;&gt;human&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22major+clinical+study%22&quot;&gt;major clinical study&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22male%22&quot;&gt;male&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22non+small+cell+lung+cancer%22&quot;&gt;non small cell lung cancer&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22organ+systems%22&quot;&gt;organ systems&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22protein+expression%22&quot;&gt;protein expression&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22randomized+controlled+trial%22&quot;&gt;randomized controlled trial&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22vascular+guide+wire%22&quot;&gt;vascular guide wire&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Hematology%22&quot;&gt;Hematology&lt;/searchLink&gt; )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background: Pemetrexed (pem) and platinum (plat) plus pembrolizumab (pembro) showed clinical improvement in metastatic nonsquamous (NSQ) non-small-cell lung cancer (NSCLC). The aim of this analysis was to assess the clinical benefit of pem+plat+pembro in patients by tumor burden at baseline. Methods: The intention-to-treat population was analysed. Patients were randomized pem+plat+pembro (n=410) or pem+plat+placebo (n=206). The data cut-off date was May 20, 2019. OS, PFS, PFS-2, and ORR were evaluated by Kaplan-Meier and univariate Cox methods within subgroups identified by extent of distant metastasis (M1a vs. M1b), median number (&#226;‰&#164;3 vs. &gt;3) of organ systems with lesions, and severity score of patient-reported symptoms (below median vs. above median) at baseline. These subgroup analyses were also replicated within PD-L1 TPS subgroups (&lt;1%, 1-49%, &#226;‰&#165;50%). Results: A consistent benefit in OS, PFS, PFS-2 and ORR was observed in the pem+plat+pembro treatment arm, compared to the pem+plat+placebo arm, irrespective of staging (M1a vs. M1b), number (&#226;‰&#164; 3 vs. 3) of organ systems with lesions and severity of patient-reported symptoms (Table 1). Results by PD-L1 expression in the subgroups were generally consistent regardless of the level of expression. Conclusions: Pem+plat+pembro demonstrated consistent clinical benefit across all subgroups analysed regardless of baseline tumor burden. These results continue to support pem+plat+pembro as a standard of care in metastatic NSQ-NSCLC. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => text )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => unknown )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/138; http://sfxhosted.exlibrisgroup.com/hfhs?sid=EMBASE&amp;issn=15387445&amp;id=doi:10.1158%2F1538-7445.AM2021-442&amp;atitle=Pemetrexed+and+platinum+plus+pembrolizumab+in+patients+with+metastatic+non-squamous+non-small+cell+lung+cancer+by+tumor+burden+at+baseline%3A+A+post-hoc+efficacy+analysis+of+KEYNOTE-189&amp;stitle=Cancer+Res.&amp;title=Cancer+Research&amp;volume=81&amp;issue=13+SUPPL&amp;spage=&amp;epage=&amp;aulast=Gadgeel&amp;aufirst=Shirish&amp;auinit=S.&amp;aufull=Gadgeel+S.&amp;coden=&amp;isbn=&amp;pages=-&amp;date=2021&amp;auinit1=S&amp;auinitm= )
Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/138 )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.D74B2BF8 )
RecordInfo Array ( [BibEntity] => Array ( [Languages] => Array ( [0] => Array ( [Text] => unknown ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => endogenous compound [Type] => general ) [1] => Array ( [SubjectFull] => pembrolizumab [Type] => general ) [2] => Array ( [SubjectFull] => pemetrexed [Type] => general ) [3] => Array ( [SubjectFull] => placebo [Type] => general ) [4] => Array ( [SubjectFull] => programmed death 1 ligand 1 [Type] => general ) [5] => Array ( [SubjectFull] => adult [Type] => general ) [6] => Array ( [SubjectFull] => cancer patient [Type] => general ) [7] => Array ( [SubjectFull] => cancer size [Type] => general ) [8] => Array ( [SubjectFull] => clinical trial [Type] => general ) [9] => Array ( [SubjectFull] => conference abstract [Type] => general ) [10] => Array ( [SubjectFull] => controlled study [Type] => general ) [11] => Array ( [SubjectFull] => distant metastasis [Type] => general ) [12] => Array ( [SubjectFull] => drug efficacy [Type] => general ) [13] => Array ( [SubjectFull] => drug therapy [Type] => general ) [14] => Array ( [SubjectFull] => female [Type] => general ) [15] => Array ( [SubjectFull] => gene expression [Type] => general ) [16] => Array ( [SubjectFull] => health care quality [Type] => general ) [17] => Array ( [SubjectFull] => human [Type] => general ) [18] => Array ( [SubjectFull] => major clinical study [Type] => general ) [19] => Array ( [SubjectFull] => male [Type] => general ) [20] => Array ( [SubjectFull] => non small cell lung cancer [Type] => general ) [21] => Array ( [SubjectFull] => organ systems [Type] => general ) [22] => Array ( [SubjectFull] => protein expression [Type] => general ) [23] => Array ( [SubjectFull] => randomized controlled trial [Type] => general ) [24] => Array ( [SubjectFull] => vascular guide wire [Type] => general ) [25] => Array ( [SubjectFull] => Hematology [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189 [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Gadgeel, Shirish ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Grey, Jhanelle ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Rizzo, Maria Teresa ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Peterson, Patrick ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kim, Jongseok ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Rodríguez-Abreu, Delvys ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2021 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-locals [Value] => edsbas ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Hematology/Oncology Meeting Abstracts [Type] => main ) ) ) ) ) ) )
IllustrationInfo